Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Serpentina Medical Science Sweden AB
AB
Bankrupt
Org 5569655698
Retail sale of pharmaceutical products
· NACE 4773
Est. 2014
0 employees
Watchlist
Share
Sweden
/
Companies
/
Retail sale of pharmaceutical products
/
Serpentina Medical Science Sweden AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2016
0M
2017
1M
2018
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2016
-1M
2017
0M
2018
Income statement
SEK thousands
Item
2016
2017
2018
Revenue
37
230
1 281
Staff expenses
—
—
—
EBITDA
−366
−777
−156
Depreciation & amort.
−9
−112
−55
EBIT
−375
−889
−211
Net financials
−31
−45
−41
Profit before tax
−405
−934
−252
Tax
−0
−0
−0
Net profit
−405
−934
−252
Balance sheet
SEK thousands
Item
2016
2017
2018
Total assets
1 251
781
1 087
Equity
634
176
112
Long-term debt
600
600
668
Short-term debt
17
5
307
Total debt
617
605
975
Financial ratios
5-year trend
EBITDA margin
-12.2%
This company
15.8%
Market median
-177% vs market
2016
2018
Equity ratio
10.3%
This company
38.2%
Market median
-73% vs market
2016
2018
Return on equity
-225.0%
This company
18.4%
Market median
-1323% vs market
2016
2018
Net profit margin
-19.7%
This company
8.1%
Market median
-343% vs market
2016
2018
Asset turnover
1.18×
This company
1.12×
Market median
+5% vs market
2016
2018
Debt / equity
8.71×
This company
0.62×
Market median
-1305% vs market
2016
2018
Annual reports & filings
Annual report 2018
Filed via Bolagsverket / SCB · Period 2017-02-01 – 2018-01-31
View
PDF
Annual report 2017
Filed via Bolagsverket / SCB · Period 2016-02-01 – 2017-01-31
View
PDF
Annual report 2016
Filed via Bolagsverket / SCB · Period 2015-02-01 – 2016-01-31
View
PDF
More on Serpentina Medical Science Sweden AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
Riskpilot